Skip to main content
. 2018 Jun 25;109(7):2315–2326. doi: 10.1111/cas.13629

Figure 4.

Figure 4

Boxplots of the differential metabolites associated with breast cancer progression. A, Boxplot showing progressive reduction of 9‐cis‐retinoic acid during progression from NC to LC to MT (NC vs LC: P = 2.349E‐5; LC vs MT: P = .00363; NC vs MT: P = 3.109E‐11). B, Boxplot showing progressive elevation of l‐dihydroorotic acid during progression from NC to LC to MT (NC vs LC: P = 2.793E‐5; LC vs MT: P = 1.571E‐6; NC vs MT: P = 1.767E‐11). C, Same as (B) but for sphingomyelin (SM)(d18:0/16:1(9Z)) (NC vs LC: P = .00488; LC vs MT: P = .01190; NC vs MT: P = 5.084E‐7). D, Same as (B) but for lysophosphatidic acid (LPA)(18:1(9Z)/0:0) (NC vs LC: P = 5.212E‐6; LC vs MT: P = 3.442E‐6; NC vs MT: P = 6.802E‐13). E, same as (B) but for sphinganine (NC vs LC: P = .04155; LC vs MT: P = .01973; NC vs MT: P = .00016). F, Same as (B) but for lysophosphatidylcholine (lysoPC)(0:0/18:0) (NC vs LC: P = .00625; LC vs MT: P = .03518; NC vs MT: P = 2.502E‐7). LC, localized breast cancer serum sample; MT, metastatic breast cancer serum sample; NC, normal control sample